Trials / Completed
CompletedNCT07267247
Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer
Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer: A Single-center Prospective Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Taichung Veterans General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.
Conditions
- Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
- Drug-Related Side Effects and Adverse Reactions (MeSH Term)
- Egfr Tyrosine Kinase Inhibitor
- Cardiotoxicity
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EGFR-TKI | Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line. |
| OTHER | EGFR tyrosine kinase inhibitor | Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
- First posted
- 2025-12-05
- Last updated
- 2025-12-05
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07267247. Inclusion in this directory is not an endorsement.